GlassScriptPhysician profile
Lawrence R Mcafee
NPI 1578574695
$2,191.36
in general payments reported to CMS, 2019-2025
30 companies · $332 in 2025
The $332 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $140 · 2021: $598 · 2022: $221 · 2023: $370 · 2024: $263 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $475.32 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $423.67 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $183.93 | 2019-2025 | |
| Novo Nordisk INC | $125.07 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $121.20 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.76 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $92.61 | 2021 | |
| Amgen INC. | $83.87 | 2021-2022 | |
| Astellas Pharma US INC | $54.84 | 2019-2025 | Veozah |
| Lilly USA, LLC | $50.32 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $48.81 | 2021-2023 | Eliquis |
| Radius Health, INC. | $46.81 | 2019-2023 | Tymlos |
| International Rehabilitative Sciences, INC | $37.96 | 2025 | Rs-4i Plus With Intersperse |
| Eisai INC. | $31.60 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $29.52 | 2019-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $29.04 | 2022 | |
| Sanofi-Aventis U.S. LLC | $26.03 | 2019 | |
| Medtronic, INC. | $25.04 | 2024 | Intellis Adaptivestim |
| Dexcom, INC. | $22.60 | 2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $22.50 | 2021 | |
| Sanofi Pasteur INC. | $20.96 | 2023 | |
| Inspire Medical Systems, INC. | $20.02 | 2024 | Inspire |
| Abbott Laboratories | $18.63 | 2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $17.18 | 2019 | |
| Acella Pharmaceuticals, LLC | $16.43 | 2025 | NP Thyroid 60 |
| Phathom Pharmaceuticals, INC. | $16.18 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $15.56 | 2021 | |
| Bioventus LLC | $14.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.03 | 2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Mcafee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.